All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @618109c on TikTok · 9s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @618109c's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Thank you for watching!

@618109c's GLP-1 disappointment is actually normal

❤️‍🔥❤️‍🔥CrisS❤️‍🔥❤️‍🔥

TikTok creator

925.6K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and activating satiety centers in the brain. Clinical trials show these medications typically produce 15-21% body weight loss over 68-72 weeks, but early results in the first month are minimal as patients start on low doses that gradually escalate.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @618109c's GLP-1 disappointment is actually normal, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@618109c's GLP-1 disappointment is actually normal is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@618109c's GLP-1 disappointment is actually normal" from ❤️‍🔥❤️‍🔥CrisS❤️‍🔥❤️‍🔥. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and activating satiety centers in the brain.

The reason this review is not generic is the source wording and the canonical claim label "glp1 after one month i only lost 10lbs and all the motivation to." In this clip, the useful excerpt is: "Thank you for watching!" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Maximum GLP-1 weight loss occurs around 68-72 weeks, not in the first month
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and activating satiety centers in the brain.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and activating satiety centers in the brain. Clinical trials show these medications typically produce 15-21% body weight loss over 68-72 weeks, but early results in the first month are minimal as patients start on low doses that gradually escalate.
  • The STEP 1 trial showed average weight loss of just 2.6 pounds in the first month on semaglutide
  • Maximum GLP-1 weight loss occurs around 68-72 weeks, not in the first month

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The STEP 1 trial showed average weight loss of just 2.6 pounds in the first month on semaglutide
  • Maximum GLP-1 weight loss occurs around 68-72 weeks, not in the first month
  • Semaglutide produced 14.9% body weight loss over 68 weeks in the STEP 1 trial
  • Tirzepatide achieved 20.9% weight loss at the highest dose over 72 weeks in SURMOUNT-1
  • Most people start on low doses (0.25mg semaglutide, 2.5mg tirzepatide) that escalate slowly
  • Ten pounds in 30 days exceeds typical early GLP-1 results and indicates good response
  • Stopping treatment after one month means missing 90% of potential weight loss benefits

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok creator claim?

@618109c says she lost only 10 pounds in one month on what appears to be a GLP-1 medication and lost all motivation to continue. The implication is that 10 pounds in 30 days represents poor results that aren't worth the effort.

She doesn't specify which GLP-1 drug she's taking or her starting dose. The video shows frustration with what she perceives as slow progress. This type of discouragement post gets hundreds of thousands of views because many people have unrealistic expectations about GLP-1 weight loss timelines.

Is 10 pounds in one month actually disappointing?

No, it's completely normal and actually on the higher end of expected early results. The STEP 1 trial (Wilding et al., NEJM, 2021) showed that participants on 2.4mg semaglutide lost an average of 2.6 pounds in the first four weeks.

Most people start GLP-1s at low doses like 0.25mg semaglutide or 2.5mg tirzepatide. You don't reach therapeutic doses for months. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found tirzepatide users lost just 1.9% of body weight in the first month.

Ten pounds in 30 days means this creator is responding well to treatment. Her expectations, not her results, are the problem.

What does realistic GLP-1 weight loss look like?

The major trials show a clear pattern: slow starts, accelerating losses, then plateau around 60-68 weeks. In STEP 1, participants reached maximum weight loss at 68 weeks with 14.9% total body weight reduction.

SURMOUNT-1 showed even better results with tirzepatide's highest dose (15mg) leading to 20.9% weight loss over 72 weeks. But month one? Barely noticeable changes for most people.

The drug manufacturers design this slow escalation on purpose. Starting with low doses reduces nausea and vomiting that can force people to quit treatment entirely.

What's driving these unrealistic expectations?

Social media posts about dramatic rapid weight loss create false benchmarks. You'll see before-and-after photos spanning months presented as if they happened quickly.

The reality is that GLP-1 medications work by slowing gastric emptying and reducing appetite through brain receptors. These mechanisms take time to show their full effects, especially as doses gradually increase.

Sustainable weight loss of 1-2 pounds per week is considered ideal by obesity medicine specialists. @618109c actually exceeded that target but still felt disappointed.

Should she really give up after one month?

Absolutely not. Stopping GLP-1 treatment after 30 days means missing the entire therapeutic benefit window. Most clinical trials don't even measure primary endpoints until 68-72 weeks for good reason.

The STEP 2 trial (Davies et al., NEJM, 2021) found that people with diabetes lost 9.6% of body weight over 68 weeks on semaglutide. Quitting at month one would mean missing 90% of potential results.

Weight loss plateaus are normal and don't indicate treatment failure. Dose adjustments and lifestyle modifications can restart progress when combined with continued medication use.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

❤️‍🔥❤️‍🔥CrisS❤️‍🔥❤️‍🔥 · TikTok creator

925.6K views on this video

after one month i only lost 10lbs and all the motivation to keep going #fyppppppppppppppppppppppp ##fyp #weightloss #journey

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial showed average weight loss of just?

The STEP 1 trial showed average weight loss of just 2.6 pounds in the first month on semaglutide

What does the video say about maximum glp-1 weight loss occurs around 68-72 weeks, not in?

Maximum GLP-1 weight loss occurs around 68-72 weeks, not in the first month

What does the video say about semaglutide produced 14.9% body weight loss over 68 weeks in?

Semaglutide produced 14.9% body weight loss over 68 weeks in the STEP 1 trial

What does the video say about tirzepatide achieved 20.9% weight loss at the highest dose over?

Tirzepatide achieved 20.9% weight loss at the highest dose over 72 weeks in SURMOUNT-1

What does the video say about most people start on low doses (0.25mg semaglutide, 2.5mg tirzepatide)?

Most people start on low doses (0.25mg semaglutide, 2.5mg tirzepatide) that escalate slowly

What does the video say about ten pounds in 30 days exceeds typical early glp-1 results?

Ten pounds in 30 days exceeds typical early GLP-1 results and indicates good response

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ❤️‍🔥❤️‍🔥CrisS❤️‍🔥❤️‍🔥, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.